{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:47:20Z","timestamp":1792928840918,"version":"4.5.0"},"reference-count":9,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"33","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2025,11,20]]},"abstract":"<jats:p>\n                    Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed\/refractory (R\/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R\/R indolent non-Hodgkin lymphoma (iNHL; 127 with FL and 31 with marginal zone lymphoma) after a median follow-up of 64.6 months. Patients underwent leukapheresis and received lymphodepleting chemotherapy and axi-cel (2 \u00d7 10\n                    <jats:sup>6<\/jats:sup>\n                    CAR T cells\/kg). The overall response rate was 90% (75% complete response rate). The median duration of response was 60.4 months, and the median progression-free survival (PFS) was 62.2 months; median time to next treatment and overall survival were not reached (NR). At data cutoff, 55% of patients were alive without requiring subsequent anticancer therapy. Median lymphoma-specific PFS in patients with FL was NR; 34% had progression or death due to lymphoma or study treatment. Notably, after 30 months postinfusion, progression or lymphoma-related deaths were rare. Late-onset toxicities were infrequent and largely unrelated to axi-cel. Durable response and prolonged survival in FL were associated with robust early CAR T-cell expansion and na\u00efve product phenotype. These findings confirm sustained responses and manageable safety with axi-cel in the long term among patients with R\/R iNHL and its potential as a curative therapy in FL.\n                  <\/jats:p>","DOI":"10.1200\/jco-25-00668","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:59:10Z","timestamp":1760644750000},"page":"3573-3577","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":27,"title":["Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03105336","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":true,"given":"Sattva S.","family":"Neelapu","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":true,"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Sehgal","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":true,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-7813","authenticated-orcid":true,"given":"Matthew L.","family":"Ulrickson","sequence":"additional","affiliation":[{"name":"Banner MD Anderson Cancer Center, Gilbert, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":true,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Lyon Sud, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-9443","authenticated-orcid":true,"given":"Pashna N.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-5065","authenticated-orcid":true,"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Wilmot Cancer Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[{"name":"Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9546","authenticated-orcid":true,"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"Columbia University Herbert Irving Comprehensive Cancer Center, New York City, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Leslie","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":true,"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":true,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[{"name":"CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Khanal","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"University of Miami Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Wulff","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8883-0727","authenticated-orcid":true,"given":"Rhine R.","family":"Shen","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangshu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Poddar","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Miao","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Nikolajeva","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0180-0654","authenticated-orcid":true,"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","unstructured":"YESCARTA (axicabtagene ciloleucel) Summary of product characteristics. Amsterdam the Netherlands Kite Pharma EU B.V. 2024"},{"key":"e_1_3_8_3_2","unstructured":"YESCARTA (axicabtagene ciloleucel) Prescribing information. Kite Pharma Inc 2024"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149"},{"key":"e_1_3_8_7_2","doi-asserted-by":"crossref","unstructured":"Cheson BD Fisher RI Barrington SF et al: Recommendations for initial evaluation staging and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3067 2014","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_3_8_9_2","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu SS","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, et al: Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141:2307-2315, 2023","journal-title":"Blood"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00838"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:00:41Z","timestamp":1763420441000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":9,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2025,11,20]]}},"alternative-id":["10.1200\/JCO-25-00668"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00668","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"2025-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}